Skip to main content

ORTHOFIX International N V Value Stock - Dividend - Research Selection

Orthofix international n v

ISIN: US68752M1080 , WKN: A2NB0X

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

Orthofix International N.V., a medical device company, provides musculoskeletal healing products and value-added services worldwide. It operates through four segments: BioStim, Extremity Fixation, Spine Fixation, and Biologics. The BioStim segment manufactures, distributes, and provides support services for bone growth stimulator devices that enhance bone fusion and are indicated as treatment to enhance fusion success rates in cervical and lumbar spine, as well as a therapeutic treatment for non-spine fractures. The Extremity Fixation segment designs, develops, and markets orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. The Spine Fixation segment designs, develops, and markets a portfolio of implant products used in surgical procedures of the spine. The Biologics segment provides a portfolio of regenerative products and tissue forms that allow physicians to treat a range of spinal and orthopedic conditions. The company markets and distributes its products through direct sales representatives; independent distributors; and employed and independent sales representatives to physicians, hospitals, ambulatory surgery centers, integrated health delivery systems, and other purchasing organizations. Orthofix International N.V. was founded in 1987 and is headquartered in Lewisville, Texas.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Orthofix Medical First Quarter 2025 Earnings: EPS Misses Expectations

2025-05-07
Orthofix Medical ( NASDAQ:OFIX ) First Quarter 2025 Results Key Financial Results Revenue: US$193.6m (up 2.7% from 1Q...

Orthofix Medical Inc (OFIX) Q1 2025 Earnings Call Highlights: Strong Growth in Orthopedics and ...

2025-05-07
Orthofix Medical Inc (OFIX) reports a robust start to 2025 with significant growth in key segments, despite facing strategic transitions and market pressures.

Q1 2025 Orthofix Medical Inc Earnings Call

2025-05-07
Q1 2025 Orthofix Medical Inc Earnings Call

Orthofix Medical Inc. 2025 Q1 - Results - Earnings Call Presentation

2025-05-06
The following slide deck was published by Orthofix Medical Inc.

Orthofix Medical Inc. (OFIX) Q1 2025 Earnings Call Transcript

2025-05-06
Orthofix Medical Inc. (NASDAQ:OFIX) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ETCompany ParticipantsJulie Dewey - Chief Investor Relations and...

Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates

2025-05-06
Orthofix (OFIX) delivered earnings and revenue surprises of 52.94% and 1.87%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?

Orthofix: Q1 Earnings Snapshot

2025-05-06
LEWISVILLE, Texas (AP) — Orthofix Medical Inc. OFIX) on Tuesday reported a loss of $53.1 million in its first quarter. On a per-share basis, the Lewisville, Texas-based company said it had a loss of $1.35.

Orthofix Reports First Quarter 2025 Financial Results

2025-05-06
LEWISVILLE, Texas, May 06, 2025--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, updated its full-year 2025 net sales guidance, and reaffirmed its full-year 2025 non-GAAP adjusted EBITDA and positive free cash flow guidance. All pro forma measures contained within this release exclude the impact of the Company’s decision to discontinue its M6-C™ and M6-L™ artificial disc product lin

Six Flags, Rapid7, and More Stocks See Action From Activist Investors

2025-04-18
13D FILINGS These disclosures are from 13Ds filed with the Securities and Exchange Commission. 13Ds are filed within 10 days of an entity’s attaining more than 5% in any class of a company’s securities.

Orthofix to Report First Quarter 2025 Financial Results

2025-04-15
LEWISVILLE, Texas, April 15, 2025--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its first quarter 2025 financial results on Tuesday, May 6, 2025 before market open. The Company will host a conference call and webcast to review results at 8:30 am Eastern Time the same day.